

Sanjay Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6083777/publications.pdf>

Version: 2024-02-01

86
papers

5,290
citations

109137

35
h-index

82410

72
g-index

87
all docs

87
docs citations

87
times ranked

4708
citing authors

#	ARTICLE	IF	CITATIONS
1	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	13.9	1,168
2	Porcine endotoxemic shock is associated with increased expired nitric oxide. <i>Critical Care Medicine</i> , 1999, 27, 385-393.	0.4	290
3	The Effects of Changes in Ventilation and Cardiac Output on Expired Nitric Oxide. <i>Chest</i> , 1997, 111, 1045-1049.	0.4	258
4	Treatment Goals of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D73-D81.	1.2	250
5	Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma. <i>Journal of Experimental Medicine</i> , 1999, 189, 1621-1630.	4.2	195
6	Role of Inducible Nitric Oxide Synthase in Pulmonary Microvascular Protein Leak in Murine Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1634-1639.	2.5	187
7	Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 192-197.	2.5	170
8	Pulmonary Neutrophil Infiltration in Murine Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 227-233.	2.5	151
9	Short-term Pulmonary Vasodilation With L-Arginine in Pulmonary Hypertension. <i>Circulation</i> , 1995, 92, 1539-1545.	1.6	149
10	Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo. <i>Respiratory Research</i> , 2015, 16, 109.	1.4	137
11	Thrombotic Arteriopathy and Anticoagulation in Pulmonary Hypertension. <i>Chest</i> , 2006, 130, 545-552.	0.4	121
12	Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H2848-H2856.	1.5	110
13	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
14	Pulmonary oxidant stress in murine sepsis is due to inflammatory cell nitric oxide*. <i>Critical Care Medicine</i> , 2005, 33, 1333-1339.	0.4	88
15	The effects of nitric oxide in acute lung injury. <i>Vascular Pharmacology</i> , 2005, 43, 390-403.	1.0	85
16	The importance of patient perspectives in pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801919.	3.1	85
17	Functional Inhibition of Constitutive Nitric Oxide Synthase in a Rat Model of Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1426-1432.	2.5	83
18	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	1.2	82

#	ARTICLE	IF	CITATIONS
19	The clinical consequences of a stiff left atrium. <i>American Heart Journal</i> , 1991, 122, 1184-1191.	1.2	71
20	EVOLUTION AND OUTCOMES OF A RAPID RESPONSE TEAM. <i>Chest</i> , 2006, 130, 218S.	0.4	68
21	Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Practice Guideline. <i>Canadian Respiratory Journal</i> , 2010, 17, 301-334.	0.8	68
22	Effects of inhaled nitric oxide in a mouse model of sepsis-induced acute lung injury*. <i>Critical Care Medicine</i> , 2002, 30, 868-873.	0.4	66
23	Pulmonary Microvascular Albumin Leak Is Associated with Endothelial Cell Death in Murine Sepsis-Induced Lung Injury In Vivo. <i>PLoS ONE</i> , 2014, 9, e88501.	1.1	66
24	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155.	1.0	65
25	The Hypotensive Effect of L-Arginine Is Associated With Increased Expired Nitric Oxide in Humans. <i>Chest</i> , 1996, 109, 1550-1555.	0.4	61
26	Sitaxsentan Treatment for Patients With Pulmonary Arterial Hypertension Discontinuing Bosentan. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 63-69.	0.3	61
27	Effects of inhaled nitric oxide in a rat model of <i>Pseudomonas aeruginosa</i> pneumonia. <i>Critical Care Medicine</i> , 2000, 28, 2397-2405.	0.4	56
28	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	1.9	51
29	Specific Role of Neutrophil Inducible Nitric Oxide Synthase in Murine Sepsis-Induced Lung Injury In Vivo. <i>Shock</i> , 2012, 37, 539-547.	1.0	49
30	Inhaled nitric oxide decreases the bacterial load in a rat model of <i>Pseudomonas aeruginosa</i> pneumonia. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 817-820.	0.3	46
31	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118.	0.4	46
32	Calpain-1 induces apoptosis in pulmonary microvascular endothelial cells under septic conditions. <i>Microvascular Research</i> , 2009, 78, 33-39.	1.1	41
33	Contribution of type I NOS to expired gas NO and bronchial responsiveness in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1997, 273, L883-L888.	1.3	40
34	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	3.1	39
35	Human Alveolar Epithelial Cells Attenuate Pulmonary Microvascular Endothelial Cell Permeability under Septic Conditions. <i>PLoS ONE</i> , 2013, 8, e55311.	1.1	37
36	The Balance Between Metalloproteinases and TIMPs. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 147, 101-131.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	1.1	33
38	Albumin leak across human pulmonary microvascular vs. umbilical vein endothelial cells under septic conditions. <i>Microvascular Research</i> , 2006, 71, 40-47.	1.1	32
39	Inducible NO synthase (iNOS) in human neutrophils but not pulmonary microvascular endothelial cells (PMVEC) mediates septic protein leak in vitro. <i>Microvascular Research</i> , 2007, 74, 23-31.	1.1	30
40	Apolipoprotein E-Deficient Mice Are Susceptible to the Development of Acute Lung Injury. <i>Respiration</i> , 2014, 87, 416-427.	1.2	29
41	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2020, 36, 977-992.	0.8	29
42	Painless Left Hemorrhagic Pleural Effusion. <i>Chest</i> , 1999, 116, 1478-1480.	0.4	27
43	Sildenafil for Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 123, 989-992.	0.4	25
44	Tissue inhibitor of metalloproteinases 3-dependent microvascular endothelial cell barrier function is disrupted under septic conditions. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H1455-H1467.	1.5	25
45	The Clinical Significance of Exhaled Nitric Oxide in Asthma. <i>Canadian Respiratory Journal</i> , 2008, 15, 99-106.	0.8	23
46	Human neutrophil-pulmonary microvascular endothelial cell interactions in vitro: Differential effects of nitric oxide vs. peroxynitrite. <i>Microvascular Research</i> , 2008, 76, 80-88.	1.1	22
47	Noninvasive Measurement of Exhaled Nitric Oxide in a Spontaneously Breathing Mouse. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1113-1116.	2.5	21
48	Effects of Nebulized Diethylenetetraamine-NONOate in a Mouse Model of Acute Pseudomonas aeruginosa Pneumonia. <i>Chest</i> , 2002, 122, 2127-2136.	0.4	19
49	Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas pneumonia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 285, L1099-L1105.	1.3	19
50	Inhibition of Murine Pulmonary Microvascular Endothelial Cell Apoptosis Promotes Recovery of Barrier Function under Septic Conditions. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	18
51	Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine. <i>Journal of Thoracic Disease</i> , 2019, 11, 21-28.	0.6	18
52	Pulmonary hypertension: diagnostic approach and optimal management. <i>Cmaj</i> , 2016, 188, 804-812.	0.9	17
53	An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease. <i>Canadian Respiratory Journal</i> , 2006, 13, 415-420.	0.8	16
54	Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 286, L1260-L1267.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 177-198.	0.2	13
56	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. <i>Diagnostics</i> , 2020, 10, 1053.	1.3	13
57	Acute respiratory failure during pregnancy: a case of nitrofurantoin-induced pneumonitis. <i>Cmaj</i> , 2007, 176, 319-320.	0.9	12
58	Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?. <i>Journal of Rheumatology</i> , 2009, 36, 216-218.	1.0	12
59	Physicians'™ and patients'™ expectations of therapies for pulmonary arterial hypertension: where do they meet?. <i>European Respiratory Review</i> , 2014, 23, 458-468.	3.0	12
60	Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1233-1240.	0.8	12
61	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. <i>Chest</i> , 2020, 158, 2270-2274.	0.4	12
62	Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 675-685.	0.3	11
63	Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial Hypertension. <i>Respiration</i> , 2015, 89, 365-373.	1.2	9
64	Pulmonary hypertension: the importance of correctly diagnosing the cause. <i>European Respiratory Review</i> , 2016, 25, 372-380.	3.0	9
65	Differential Mechanisms of Septic Human Pulmonary Microvascular Endothelial Cell Barrier Dysfunction Depending on the Presence of Neutrophils. <i>Frontiers in Immunology</i> , 2018, 9, 1743.	2.2	9
66	Treatment of pulmonary hypertension associated with COPD: a systematic review. <i>ERJ Open Research</i> , 2022, 8, 00348-2021.	1.1	9
67	Endogenous pulmonary nitric oxide in the regulation of airway microvascular leak. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L961-L968.	1.3	8
68	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005095.	0.9	8
69	Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: A qualitative systematic review. <i>Canadian Journal of Cardiology</i> , 2009, 25, e63-e68.	0.8	7
70	Hemoptysis caused by erosion of thoracic aortic aneurysm. <i>Cmaj</i> , 2010, 182, E186-E186.	0.9	7
71	Modulation of neutrophil apoptosis by murine pulmonary microvascular endothelial cell inducible nitric oxide synthase. <i>Biochemical and Biophysical Research Communications</i> , 2010, 401, 207-212.	1.0	7
72	Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. <i>Canadian Respiratory Journal</i> , 2005, 12, 303-315.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Changing face of pulmonary arterial hypertension in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 242-252.	0.2	5
74	Quantification of adherens junction disruption and contiguous paracellular protein leak in human lung endothelial cells under septic conditions. Microcirculation, 2019, 26, e12528.	1.0	5
75	Effect of Hemolyzed Plasma on the Batch Measurement of Nitrate by Nitric Oxide Chemiluminescence. Clinical Chemistry, 2001, 47, 1847-1851.	1.5	4
76	Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Canadian Journal of Cardiology, 2005, 21, 909-14.	0.8	4
77	Delayed rectifier potassium channels contribute to the depressed pulmonary artery contractility in pneumonia. Journal of Applied Physiology, 2002, 93, 957-965.	1.2	3
78	Predicting Postoperative FEV1 Using Spiral Computed Tomography. Academic Radiology, 2010, 17, 607-613.	1.3	3
79	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.2	3
80	SPECT/CT versus planar imaging to determine treatment strategy for non-small-cell lung cancer: a cost-effectiveness analysis. Journal of Comparative Effectiveness Research, 2022, , .	0.6	3
81	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	1.3	2
82	Treatment of Pulmonary Arterial Hypertension: Great Expectations!. Journal of Rheumatology, 2011, 38, 403-405.	1.0	1
83	Nuclear imaging in chronic thromboembolic pulmonary hypertension: increasingly central to diagnosis and management. Journal of Nuclear Cardiology, 2022, 29, 3401-3404.	1.4	1
84	Cardiopulmonary Monitoring of Patients with Pulmonary Hypertension and Right Ventricular Failure. , 2021, , 871-903.		0
85	Pulmonary vascular diseases. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 108-113.	0.2	0
86	Caspase-Dependent Septic Pulmonary Microvascular Endothelial Cell Barrier Dysfunction is Associated with Vascular Endothelial-Cadherin Disruption. FASEB Journal, 2018, 32, 35.8.	0.2	0